

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.

Chordate Medical Holding AB (publ) announces the outcome of warrants of series TO 8

Chordate Medical Holding AB (publ) ("Chordate Medical" or the "Company") announces today the outcome of the exercise of warrants of series TO 8, that were issued in connection with the Company's rights issue of units in February 2024. In total, 64,126,500 warrants of series TO 8 were exercised, corresponding to approximately 50.2 percent of the total number of outstanding warrants of series TO 8, for subscription of 128,253 shares in the Company at a subscription price of SEK 23.99 per share. Chordate Medical will receive approximately SEK 3,076,789.47 before issue costs through the exercise of warrants of series TO 8.

Background

The subscription period for exercise of the warrants of series TO 8 took place from and including November 4, 2024, up to and including November 18, 2024. The subscription price per share for exercising the warrants of series TO 8 was set to SEK 23.99.

In total, 64,126,500 warrants of series TO 8 were exercised for subscription of 128,253 shares in the Company, meaning that approximately 50.2 percent of the total number of outstanding warrants of series TO 8 were exercised for subscription of new shares in Chordate Medical.

Exercised warrants will be replaced by shares after the new issue has been registered with the Swedish Companies Registration Office. The registration of shares is expected to take place within approximately two (2) weeks.

Number of shares, share capital and dilution

Through the exercise of the warrants of series TO 8, the number of shares in the Company will increase by 128,253 shares, from 980,223 shares to 1,108,476 shares, and the share capital will increase with SEK 1,282,530 from SEK 9,802,230 to SEK 11,084,760.

For existing shareholders who did not exercise any warrants of series TO 8, the dilution amounts to approximately 11.6 percent of the number of shares and votes in the Company.

Advisors

Vator Securities AB act as financial advisor and CMS Wistrand Advokatbyrå act as legal advisor to Chordate Medical in connection with the exercise of the warrants of series TO 8. Vator Securities also act as issuer agent in connection with the exercise of the warrants of series TO 8.

Press Release
20 November 2024 13:15:00 CET

CHORDATE
M E D I C A L

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked Ozilia® Migraine, a neuromodulation and drug-free treatment technology for chronic migraine and chronic rhinitis. The treatment has clinically proven efficacy according to a recent study, and is marketed in selected markets in the EU and the Middle East. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Vator Securities AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Attachments

[Chordate Medical Holding AB \(publ\) announces the outcome of warrants of series TO 8](#)